Bio-Rad Laboratories Inc. Class A Common Stock (BIO)

FairStock Score: 70/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Bio-Rad through a Graham-and-Buffett lens: understandable products, recurring demand, and a price that leaves room for error. Bio-Rad sells life science research tools and clinical diagnostics. In fiscal 2025, the year ended 2025-12-31, revenue was $2.6B, net income was $759.9M, and diluted EPS was $27.85. But fiscal 2024 showed a net loss of $1.8B, or diluted EPS of -$65.36, and fiscal 2023 a net loss of $637.3M, or diluted EPS of -$21.82. The latest fiscal Q2 2026, the quarter ended 2026-06-30, had revenue of $651.0M, net income of $371.4M, and diluted EPS of $13.85. That is a striking profit, but fiscal Q1 2026 had a net loss of $527.1M, or diluted EPS of -$19.55. So the earnings record is volatile. The balance sheet looks reasonable: D/E of 0.19, Altman Z-Score of 3.32, and trailing free cash flow of $353.1M. Still, FairStock calculations show ROE of 3.11% and ROCE of 1.66%, which are low for a quality business. At the close on 2026-10-13, the price was $363.73, with a market cap of $9.8B. FairStock's P/E is 44.30, P/B is 1.36, PEG is 2.63, and EV/EBITDA is 18.68. Its Graham Number is $222.62, giving a margin of safety of -63.39%. I would want steadier profits, better returns on capital, and some revenue growth before treating this as a bargain.

In plain English: Bio-Rad makes tools and tests for life science research and clinical diagnostics. The business has swung between losses and profits, but its latest reported quarter was very profitable and it carries little debt. The stock price looks expensive compared with its accounting value and a conservative value estimate.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer